Clinical Edge Journal Scan

Obesity tied to increased risk for colorectal cancer in patients with Lynch syndrome


 

Key clinical point: Obesity is a significant risk factor for colorectal cancer (CRC) in men with Lynch syndrome (LS). Moreover, obesity significantly increased CRC risk in patients with a mutation in mismatch repair gene MLH1.

Major finding: Obesity was associated with a significant 2-fold higher risk for CRC in men (summary relative risk [SRR], 2.09; 95% confidence interval [CI], 1.23-3.55) but not in women. Also, the mutation in MLH1 significantly increased the risk for CRC by 49% for every increase of 5 kg/m 2 (SRR, 1.49; 95% CI, 1.11-1.99).

Study details: Findings are from a meta-analysis of 4 observational studies that reported obesity and risk for CRC in patients with LS. The number of patients varied from 265 to 3,595.

Disclosures: This research received no external funding. The authors declared no conflicts of interest.

Source: Lazzeroni M et al. Nutrients. 2021 May 20. doi: 10.3390/nu13051736 .

Recommended Reading

First AI device for colonoscopy: Extra set of expert ‘eyes’
MDedge Hematology and Oncology
Does surgery for colorectal liver metastases release tumor cells?
MDedge Hematology and Oncology
CRC screening guidelines: 45 is the new 50, and 85 is the new 75
MDedge Hematology and Oncology
NPs and PAs performing colonoscopies: Why not?
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Colorectal Cancer July 2021
MDedge Hematology and Oncology
Continuation of screening endoscopy beyond age 75 prevents CRC incidence and death
MDedge Hematology and Oncology
Perioperative systemic therapy feasible and safe in patients with resectable colorectal peritoneal metastases
MDedge Hematology and Oncology
HLX04, an alternative biosimilar to bevacizumab for refractory/metastatic colorectal cancer
MDedge Hematology and Oncology
Cumulative social risk linked to reduced receipt of chemotherapy in patients with advanced CRC
MDedge Hematology and Oncology
Anlotinib substantially prolongs PFS in metastatic CRC
MDedge Hematology and Oncology